Lilly Covid antibodies cut hospitalizations and deaths

Washington (AFP) – US pharmaceutical company Eli Lilly’s combination of two synthetic antibodies against Covid-19 reduced hospitalizations and deaths by 70 percent in high-risk patients with recent positive tests, the company said Tuesday. “Bamlanivimab and etesevimab together have the potential to be an important treatment that significantly reduces hospitalizations and death in high-risk COVID-19 patients,” Lilly’s chief scientific officer Daniel Skovronsky said. The results meant that the phase 3 trial involving 1,035 people achieved its main goal, and the study also met its secondary goals…

Read More

HEDGE accordingly